Skip to main content
Have a personal or library account? Click to login
New Therapies for Hepatitis C Virus Cover

New Therapies for Hepatitis C Virus

Open Access
|Dec 2015

References

  1. 1. Hepatitis C. WHO. Available at: www.who.int/mediacentre/factsheets/fs164/en/. Accessed October 1, 2015.
  2. 2. SC Rey and DL Thomas. "Hepatitis C" (Chapter 156). In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, edited by JE Bennett, R Dolin, MJ Blaser. Philadelphia: Elsevier, 2015.
  3. 3. American Association for the Study of Liver Diseases/ Infectious Diseases Society of America/International Antiviral Society-USA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. Available at: www.hcvguidelines.org. Accessed October 1, 2015.
  4. 4. JM Pawlotsky et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015; 62: S87.10.1016/j.jhep.2015.02.00625920094
  5. 5. EASL Recommendations on treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199..10.1016/j.jhep.2015.03.02525911336
  6. 6. Telaprevir (Incivek) and Boceprevir (Victrelis) for Chronic Hepatitis C. Med Lett Drugs Ther. 2011; 53: 57.
  7. 7. Drugs for Hepatitis C. Med Lett Drugs Ther. 2012; 54: 81.
  8. 8. Simeprevir (Olysio) for Chronic Hepatitis C. Med Lett Drugs Ther. 2014; 56: 1.
  9. 9. Sofosbuvir (Sovaldi) for chronic hepatitis C. Med Lett Drugs Ther. 2014; 56: 5.
  10. 10. A Combination of Ledipasvir and Sofosbuvir (Harvoni) for Hepatitis C. Med Lett Drugs Ther. 2014; 56: 112.
  11. 11. A 4-Drug Combination (Viekira Pak) for Hepatitis C. Med Lett Drugs Ther. 2015; 57: 15.
  12. 12. Daclatasvir (Daklinza) for HCV Genotype 3 Infection. Med Lett Drugs Ther. 2015; 57: 142.
  13. 13. In brief: severe bradycardia with sofosbuvir and amiodarone. Med Lett Drugs Ther. 2015; 57: 58.
  14. 14. JM Collins et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015; 61: 130410.1093/cid/civ47426082511
  15. 15. SD Safran. HIV coinfected have similar SVR rates as HCV monoinfected with DAAs: It's time to end segregation and integrate HIV patients into HCV trials. Clin Infect Dis. 2015; 61: 1127.10.1093/cid/civ43826060286
  16. 16. SB Trooskin et al. Access to costly new hepatitis C drugs: medicine, money, and advocacy. Clin Infect Dis (2015) doi: 10.1093/cid/civ677 (First published online: August 12, 2015) 10.1093/cid/civ67726270682
DOI: https://doi.org/10.1515/prilozi-2015-0060 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Language: English
Page range: 119 - 132
Published on: Dec 30, 2015
In partnership with: Paradigm Publishing Services
Publication frequency: 3 issues per year

© 2015 Hari Polenakovik, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.